Supplemental Materials Molecular Biology of the Cell

Dalton et al.

Figure S1: Sorting of the Snc1 chimera and Neo1 is not affected in Vps13 point mutantsA) Invertase activity overlay assay shows that plasmids expressing wild-type and mutant forms of Vps13 are able to restore GSS localization in a *vps13* Δ mutant (upper panel). Cell surface chimera levels were quantified by densitometry (lower panel). a.u. (arbitrary units), n=3, One-Way ANOVA with a Dunnett-corrected post-hoc test: ****p<0.0001.B) The Neo1 accumulation in large puncta seen in *vps13* Δ mutants was complemented by wild-type and mutant pVps13 plasmids. Top: live-cell fluorescence microscopy of *vps13* Δ strains co-expressing pADHpr-GFP-Neo1 and Vps13 wild-type or mutant plasmids. Scale bar, 2µm. Bottom: quantification of the number of large Neo1 puncta/cell. Error bars report standard error of the mean, >300 cells/trial, n=4.One-Way ANOVA with a Dunnett-corrected post-hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.001.

Figure S2: Identification of mutants that cause Golgi retention of Neo1 A) Plot of Neo1/Sec7 colocalization versus the average number of Neo1 puncta/cell. Indicated mutants were subject to further analysis. B) Quantitation after small-scale re-imaging identifies a subset of mutants with increased Neo1/Sec7 colocalization. Error bars report standard error of the mean, >300 cells/trial, n=3. One-Way ANOVA with a Dunnett-corrected post hoc test: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Figure S3: The Snx3 sorting signal is present in the first 195 amino acids of Neo1. A) Representative live-cell fluorescence images of strains expressing GFP-Neo1-ALP truncation mutants and stained with the vacuolar dye FM4-64. (B) Live-cell fluorescence microscopy shows a second Snx3 sorting signal downstream of amino acid 140 may be active in the GFP-Neo1-ALP chimera. Left: representative images. Scale bar, 2µm. Right: percentage of cells showing GFP-Neo1-ALP at vacuolar rim. Error bars report standard error of the mean, >100 cells/trial, n=3. One-Way ANOVA with a Dunnettcorrected post hoc test comparisons to wild-type (1-195): *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. C) Quantitation of vacuolar localization. Left: Schematic representation of truncation mutants. Right: Percentage of cells showing GFP-Neo1-ALP at the vacuolar rim, >100 cells, n=1.

Figure S4: T-Coffee alignment of the Neo1 N-terminal tail in *Saccharomyces cerevisiae* and other closely related yeasts. Colors reflect the JalviewClustalX color scheme.

Figure S5: TheN-terminal tail of Neo1 is not essential for viability. 10x serial dilutions of strains expressing the wild-type or mutant forms of pGFP-Neo1 under the native promoter, or an empty vector control, were grown on selective medium containing galactose (SG-URA) or dextrose (SD-URA) to repress *GAL1pr-NEO1* expression. Plates were incubated at 30°C or 37°C for 36 hours. All mutant forms of Neo1 supported viability even at high temperatures.

Figure S6:Trifluoperazine sensitivity may reflect changes in lipid asymmetry. 10x serial dilutions of strains expressing the indicated wild-type and mutant forms of pGFP-Neo1 under the native promoter were grown on glucose-containing media (YPD +/- trifluoperazine) to repress expression of *GALpr-NEO1*.

Figure S7: The Neo1 FEM>AAA mutation does not cause missorting of the CPY receptor Vps10. Serial dilutions (1:2) of strains were grown on synthetic medium containing dextrose to repress *GALpr-NEO1* expression in applicable strains. Plates were incubated at 30°C for 16 hours with a nitrocellulose disc overlay, which was probed for the presence of CPY. The numbers above the blot indicate the concentration of yeast in OD_{600}/mL

Table S1 Genome-wide invertase z scores

Table S2 Genes identified in the CLIK group for mutants with reduced cell surface GSS levels.

Table S3 High Content Imaging T-statistic raw values.

Table S4 Yeast Strains used in this study

Table S5 Plasmids used in this study.

A pVps13 pRS416 L1627S

pVps13

pVps13 D716H









35



Neo1 puncta/cell (t-statistic)



Saccharomycescerevisiae YJM993/1-195 Naumovozymacastellii/CBS4309/1-205 Kazachstaniaafricana CBS2517/1-183 Candidaglabrata/1-189 Torulasporadelbrueckii/1-194 Zygosaccharomycesrouxii/1-190 Vanderwaltozymapolyspora/1-171 LachanceathermotoleransCBS6340/1-178 Kluyveromycesmarxianus/1-198 Kluyveromyceslactis/1-198

Consensus

SaccharomycescerevisiaeYJM993)/1-195 Naumovozymacastelli/CBS4309)/1-205 KazachstaniaafricanaCBS2517)/1-183 Candidagibarta]/1-189 Torulasporadelbrueckilj/1-194 Zygosaccharomycesrouxii]/1-190 Vanderwaltozymapolyspora/1-171 LachanceathermotoleransCBS6340)/1-178 Kluyveromycesmarkianus/1-198 Kluvveromycesalactis/1-198

Consensus

SaccharomycescerevisiaeYJM993j/1-195 NaumovozymacastelliiCBS4309/1-205 KazachstaniaafricanaCBS2517j/1-183 Candidaglabrata/1-189 Torulasporadelbrueckilj/1-194 Zygosaccharomycesrouxilj/1-190 Vanderwaltozymapolyspora/1-171 LachanceathermotoleransCBS6340j/1-178 Kluyveromycesmarxianus/1-198 Kluyveromyceslactis/1-198

Consensus



KRKSK-SSL+SK--S---YRST+--SIELNDQHVEREIHPDTTPVYDRNKYPSNEISNAKYNAFTFIPTLLYEQFK





GALpr-NEO1

YPD + 45µM Trifluoperazine

0.5 0.25 0.125



pNeo1

pNeo1 (FEM>AAA)

snx3∆ + pNeo1

snx3∆ + pNeo1 (FEM>AAA)

GALpr-NEO1